Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patientsElisabetta Schiaroli, Daniela Francisci, Anna Gidari et al.|Journal of Clinical Virology|2023Cited by 3
Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)Enrico Tiacci, Gianna Maria D’Elia, Simone Ferrero et al.|HemaSphere|2025Cited by 1